{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-035882","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.955324+00:00","generated_at":"2026-05-26T03:48:51.055770+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Taysha reports FY2024 net loss $89.3M; TSHA-102 well tolerated in all 10 patients across REVEAL trials","bullets":["Net loss $89.3M ($0.36/sh) vs $111.6M ($0.96/sh) in FY2023; cash $139.0M, runway into Q4 2026.","TSHA-102 (Rett syndrome) no treatment-related SAEs or DLTs in all 10 patients (6 high dose, 4 low dose) as of Feb 17, 2025 cutoff.","Dosing of Part A in both REVEAL Phase 1/2 trials completed; pivotal trial design update expected H1 2025.","R&D expenses $66.0M (up $9.2M YoY) driven by GMP manufacturing and clinical activities; G&A $29.0M (down $1.0M).","Safety and efficacy data from high-dose cohorts (n=3 each) and low-dose updates expected H1 2025 for both adolescent/adult and pediatric trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-035882","json":"https://secwatch.observer/filing/0001193125-25-035882.json","markdown":"https://secwatch.observer/filing/0001193125-25-035882.md","text":"https://secwatch.observer/filing/0001193125-25-035882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/0001193125-25-035882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525035882/d920809d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:48:51.055770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}